Merck (MRK) Amortizatization of Intangibles (2020 - 2026)
Merck (MRK) reported Amortizatization of Intangibles of $931.0 million for Q1 2026, up 55.95% year-over-year from $597.0 million in Q1 2025, and down 4.32% quarter-over-quarter from $973.0 million in Q4 2025.
Merck (MRK) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Merck (MRK) has 7 years of Amortizatization of Intangibles data on file, last reported at $931.0 million in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $931.0 million, up 55.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 24.18% YoY), and the FY2025 annual result was $2.8 billion, up 16.62% from the prior year.
- Amortizatization of Intangibles declined to $931.0 million in Q1 2026 per MRK's latest filing, from $973.0 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $973.0 million in Q4 2025 and troughed at $460.0 million in Q3 2022.
- A 5-year average of $602.8 million and a median of $597.0 million in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2026: Amortizatization of Intangibles declined 22.32% in 2023, then soared 55.95% in 2026.
- A 5-year view of Amortizatization of Intangibles shows it stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then jumped by 46.1% to $675.0 million in 2024, then surged by 44.15% to $973.0 million in 2025, then decreased by 4.32% to $931.0 million in 2026.
- Business Quant data shows MRK's Amortizatization of Intangibles at $931.0 million in Q1 2026, $973.0 million in Q4 2025, and $623.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 931.00 Mn |
| Mar 31, 2026 | 931.00 Mn |
| Dec 31, 2025 | 973.00 Mn |
| Dec 31, 2025 | 973.00 Mn |
| Sep 30, 2025 | 623.00 Mn |
| Sep 30, 2025 | 623.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Mar 31, 2025 | 597.00 Mn |
| Mar 31, 2025 | 597.00 Mn |
| Dec 31, 2024 | 675.00 Mn |
| Dec 31, 2024 | 675.00 Mn |
| Sep 30, 2024 | 633.00 Mn |
| Sep 30, 2024 | 633.00 Mn |
| Jun 30, 2024 | 614.00 Mn |
| Jun 30, 2024 | 614.00 Mn |
| Mar 31, 2024 | 473.00 Mn |
| Mar 31, 2024 | 473.00 Mn |
| Dec 31, 2023 | 462.00 Mn |
| Dec 31, 2023 | 462.00 Mn |